Why the study?
Do emerging pharmacological treatments prevent abdominal aortic aneurysm growth and rupture?
Population
Patients with abdominal aortic aneurysm (AAA) and preclinical animal models of AAA
Design
Review
Key result
Various pharmacological agents, including statins, RAS blockers, and tetracyclines, are being investigated to slow abdominal aortic aneurysm expansion, though established drug therapies are currently lacking.
Authors
Loading...
No proven therapies exist to slow AAA expansion; leaves open the need for RCTs to identify effective agents.
Do emerging pharmacological treatments prevent abdominal aortic aneurysm growth and rupture?
This review highlights emerging pharmacological targets, such as statins, RAS blockers, and doxycycline, that may slow abdominal aortic aneurysm expansion and reduce the need for surgical intervention.
Fraga‐Silva et al. (2015) conducted a review in Abdominal aortic aneurysm. Pharmacological treatments (statins, RAS blockers, tetracyclines, etc.) was evaluated. Various pharmacological agents, including statins, RAS blockers, and tetracyclines, are being investigated to slow abdominal aortic aneurysm expansion, though established drug therapies are currently lacking.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: